Molecular Partners AG
SIX:MOLN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Molecular Partners AG
Research & Development
Molecular Partners AG
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Research & Development
-CHf41.5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Research & Development
-$283.4m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Research & Development
-CHf81.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Research & Development
-CHf98.4m
|
CAGR 3-Years
37%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Research & Development
-CHf8.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Research & Development
-CHf1.2m
|
CAGR 3-Years
62%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's Research & Development?
Research & Development
-41.5m
CHF
Based on the financial report for Sep 30, 2025, Molecular Partners AG's Research & Development amounts to -41.5m CHF.
What is Molecular Partners AG's Research & Development growth rate?
Research & Development CAGR 3Y
19%
Over the last year, the Research & Development growth was 34%. The average annual Research & Development growth rates for Molecular Partners AG have been 19% over the past three years .
